CYP2C19 基因型对经皮冠状动脉介入治疗后围术期心肌梗死的相关性研究

2016-09-26 02:13:45陈虹陈慧
中国循环杂志 2016年8期
关键词:支架

陈虹 ,陈慧

冠心病研究

CYP2C19 基因型对经皮冠状动脉介入治疗后围术期心肌梗死的相关性研究

陈虹 ,陈慧

目的:分析影响 经皮冠状动脉(冠脉)介入治疗(PCI)围术期心肌梗死(PMI)危险因素,探讨 CYP2C19 基因型对PMI 的影响。

方法:入选 PCI 术前肌钙蛋白I(cTnI)阴性的 283 例行择期 PCI 的冠心病患者,术中未发生与介入相关的不良反应;术后 24 h内复查 cTnI ,根据 cTnI 是否大于 5 倍正常参考值上限,将患者分为 PMI 组(n=83)和非 PMI 组(n=200);CYP2C19 基因用 DNA 微阵列检测,并根据结果将患者分为快代谢型(1*/*1)、中间代谢型(1*/*2 或 1*/*3)和慢代谢型(2*/*2 或 2*/3*或 3*/*3);二磷酸腺苷(ADP) 抑制率通过血栓弹力图检测,定义 ADP 抑制率≤20%为残余血小板高反应性(HPR)。比较 PMI 组和非 PMI组临床基线情况,并分析 CYP2C19 基因型等各因素对 PMI 的影响。

结果:PMI发生率为 29.3%(83/283); 两组在年龄、性别、体重指数(BMI)、吸烟、总胆固醇、低密度脂蛋白胆固醇、尿酸及高血压病和糖尿病等情况差异无统计学意义(P>0.05);而 PMI 组与非 PMI 组相比:平均置入支架个数更多[(2.1±0.9)个 vs (1.5±0.6)个,P<0.05)、支架总长度更长[56(36~71) mm vs 33(23~51)mm,P<0.05]、ADP抑制率更低[(36.0±29.8)% vs (43.9±26.4)%,P=0.02)、 HPR 发生率更高(39.8% vs 22.0%,P=0.01),差异均有统计学意义;CYP2C19快代谢型、中间代谢型和慢代谢型的比例分别为 37.5%、45.2%和 17.3%;各型中 PMI 患者所占比例分别是 21.7%、29.7%、44.9%;Logistic 回归分析示,HPR[OR=2.18,95%可信区间(CI):1.19~4.01,P=0.02]、支架总长度(OR=1.03,95%CI:1.00~1.06,P=0.007)、CYP2C19 慢代谢型基因(OR=2.8,95%CI 1.24~6.28,P=0.01)是PMI发生的危险因素。

结论:HPR、置入支架总长度、CYP2C19 慢代谢型是 PMI 发生的危险因素;而 CYP2C19 慢代谢型可能是最重要的内源性因素。

血管成形术,经腔,经皮冠状动脉;围术期心肌梗死;CYP2C19 基因

Abstract

Objective:To analyze the risk factors for peri-procedural myocardial infarction (PMI) in patients with percutaneous coronary intervention (PCI) and to study the impact of CYP2C19 genotypes on PMI.

Methods:A total of 283 coronary artery disease (CAD) patients received elective PCI were enrolled,the patients were with normal level of cTnI prior PCI,without adverse reaction post PCI and cTnI levels were re-examined at 24 hours after PCI. The patients were divided into 2 groups: PMI group,n=83 and Non-PMI group,n=200. CYP2C19 genotypes were detected by DNA microarray chip method and based on its result,the patients were classified into 3 genotypes: Extensive metabolism type,Intermediate metabolism type and Poor metabolism type. The patients with ADP inhibition rate ≤ 20% was defined as heightened platelet reactivity (HPR) which was measured by thrombelastograph. Baseline clinical condition was compared between 2 groups and the impact of CYP2C19 genotypes with other risk factors for PMI occurrence were studied.

Results:The occurrence rate of PMI was 29.3% (83/283); the age,gender,BMI,smoking,blood levels of TG,LDL-C and uric acid,history of hypertension and diabetes were similar between 2 groups,P>0.05. Compared with Non-PMI group,PMI group had more implanted stents (2.1 ± 0.9) vs (1.5 ± 0.6) and longer total length of stents 56 (36-71) mm vs 33 (23-51) mm,both P<0.05; lower ADP inhibition rate (36.0 ± 29.8) % vs (43.9 ± 26.4) %,P=0.02 and higher HPR occurrence rate 39.8% vs 22.0%,P=0.01. The ratios of CYP2C19 genotypes of Extensive metabolism,Intermediate metabolism and Poor metabolism were 37.5%,45.2% and 17.3% respectively,while PMI patients in each genotype were 21.7%,29.7% and 44.9% respectively. Logistic regression analysis indicated that HPR (OR=2.18,95% CI 1.19-4.01,P=0.02),total length of stents (OR=1.03,95% CI 1.00-1.06,P=0.007) and CYP2C19 Poor metabolism genotype (OR=2.8,95% CI 1.24-6.28,P=0.01) were the risk factors for PMI occurrence.

Conclusion:HPR,total length of stents and CYP2C19 poor metabolism genotype were the risk factors of PMI occurrence,while poor metabolism genotype might be the most important endogenous reason for PMI occurrence.

(Chinese Circulation Journal,2016,31:742.)

围手术期心肌梗死(PMI)是经皮冠状动脉(冠脉)介入治疗(PCI)后最常见的并发症,其范围包括轻度的心肌酶升高,甚至到大面积的心肌梗死,是多因素相互作用的病理生理过程,而氯吡格雷治疗后血小板高反应性(HPR)可增加PMI的发生风险[1]。……

登录APP查看全文

猜你喜欢
支架
支架≠治愈,随意停药危害大
保健医苑(2022年5期)2022-06-10 07:46:12
给支架念个悬浮咒
一种便携式侧扫声呐舷侧支架的设计及实现
右冠状动脉病变支架植入后显示后降支近段肌桥1例
三维多孔电磁复合支架构建与理化表征
前门外拉手支架注射模设计与制造
模具制造(2019年3期)2019-06-06 02:10:54
基于ANSYS的轮毂支架结构设计
血管内超声在冠状动脉支架置入中的应用与评价
下肢动脉硬化闭塞症支架术后再狭窄的治疗
星敏感器支架的改进设计
航天器工程(2014年5期)2014-03-11 16:35:55